Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers of cancer metastasis through the lymphovascular system: future perspectives

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Cancer progression from the primary site to the regional lymph nodes and beyond to the distant sites through the lymphovascular system is genetically determined. In general, sentinel lymph node in the regional lymph nodes is the gateway for metastasis. Biomarkers are becoming increasingly important to define different phases of metastasis. With further understanding of the molecular mechanisms of metastasis, more targets are available for selective therapeutic intervention so that effective therapy can be delivered against cancer in a more personalized approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leong SP (2006) Proceedings of the 1st International Symposium on Cancer Metastasis and Lymphovascular System: basis for rational therapy, 28–30 April 2005, San Francisco, California, USA. Cancer Metastasis Rev 25(2):157–294

  2. Leong SP (2007) Cancer metastasis and the lymphovascular system : basis for rational therapy. Cancer treatment and research. Springer, New York

    Book  Google Scholar 

  3. Leong SP (2009) From local invasion to metastatic cancer; involvement of distant sites through the lymphovascular system. Humana Press/Springer, New York

    Google Scholar 

  4. Leong SP (2011) The pivotal role of the lymphovascular system in cancer metastasis. J Surg Oncol 103:639–641

    Article  PubMed  Google Scholar 

  5. Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399

    Article  PubMed  CAS  Google Scholar 

  6. Reintgen D, Cruse CW, Wells K et al (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220:759–767

    Article  PubMed  CAS  Google Scholar 

  7. Leong SP (2004) Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 11:192S–197S

    PubMed  Google Scholar 

  8. Morton DL, Cochran AJ, Thompson JF (2005) Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242:302–311; discussion 311–313

    PubMed  Google Scholar 

  9. Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol 12:2229–2234

    PubMed  CAS  Google Scholar 

  10. Leong SP, Gershenwald JE, Soong SJ et al (2011) Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol 103:538–549

    Article  PubMed  Google Scholar 

  11. Thompson JF, Soong SJ, Balch CM et al (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29:2199–2205

    Article  PubMed  Google Scholar 

  12. Gershenwald JE, Soong SJ, Balch CM (2010) TNM staging system for cutaneous melanoma…and beyond. Ann Surg Oncol 17:1475–1477

    Article  PubMed  Google Scholar 

  13. Baehner FL, Li R, Jenkins T et al (2012) The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. Ann Surg Oncol 19:1034–1042

    Article  PubMed  Google Scholar 

  14. Futreal PA, Coin L, Marshall M et al (2004) A census of human cancer genes. Nat Rev Cancer 4:177–183

    Article  PubMed  CAS  Google Scholar 

  15. Baehner FL, Lee M, Demeure MJ et al (2011) Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 103:563–573

    Article  PubMed  CAS  Google Scholar 

  16. Becker D, Mihm MC, Hewitt SM et al (2006) Markers and tissue resources for melanoma: meeting report. Cancer Res 66:10652–10657

    Article  PubMed  CAS  Google Scholar 

  17. Murphy MJ (2012) Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. Humana Press/Springer, New York

    Book  Google Scholar 

  18. Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10:811–812

    Article  PubMed  CAS  Google Scholar 

  19. Beecher C (2002) Metabolomics: the newest “omics” sciences. Innov Pharm Technol 2:57–64

    Google Scholar 

  20. Witte MH (2011) Translational/personalized medicine, pharmaco/surgico/radiogenomics, lymphatic spread of cancer, and medical ignoromes. J Surg Oncol 103:501–507

    Article  PubMed  Google Scholar 

  21. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1–10

    Article  PubMed  CAS  Google Scholar 

  22. van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009

    Article  PubMed  Google Scholar 

  23. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 346:1937–1947

    Article  PubMed  Google Scholar 

  24. Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570–580

    Article  PubMed  CAS  Google Scholar 

  25. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  26. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  PubMed  CAS  Google Scholar 

  27. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  PubMed  CAS  Google Scholar 

  28. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819

    Article  PubMed  CAS  Google Scholar 

  29. Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363–366

    Article  PubMed  CAS  Google Scholar 

  30. Weinberg RA (2007) The biology of cancer. Garland Science, New York

    Google Scholar 

  31. Paget G (1889) Remarks on a case of alternate partial anaesthesia. Br Med J 1:1–3

    Article  PubMed  CAS  Google Scholar 

  32. McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235

    Article  PubMed  Google Scholar 

  33. Nass SJ, Moses HL (eds) (2007) Cancer biomarkers: the promises and challenges of improving detection and treatment. National Academies Press, Washington

    Google Scholar 

  34. Hellman S (1997) Darwin’s clinical relevance. Cancer 79:2275–2281

    Article  PubMed  CAS  Google Scholar 

  35. Tobler NE, Detmar M (2006) Tumor and lymph node lymphangiogenesis—impact on cancer metastasis. J Leukoc Biol 80:691–696

    Article  PubMed  CAS  Google Scholar 

  36. Rinderknecht M, Detmar M (2008) Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 216:347–354

    Article  PubMed  CAS  Google Scholar 

  37. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456

    Article  PubMed  CAS  Google Scholar 

  38. Morton DL, Hoon DS, Cochran AJ (2003) Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238:538–549; discussion 549–550

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Melanoma Research and Treatment, Department of Surgery, California Pacific Medical Center and Sutter Pacific Medical Foundation, California Pacific Medical Center Research Institute, 2340 Clay Street, 2nd Floor, San Francisco, CA, 94115, USA

    Stanley P. L. Leong

  2. Department of Surgery, University of Arizona College of Medicine, Tucson, AZ, USA

    Marlys Witte

Authors
  1. Stanley P. L. Leong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marlys Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanley P. L. Leong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leong, S.P.L., Witte, M. Biomarkers of cancer metastasis through the lymphovascular system: future perspectives. Clin Exp Metastasis 29, 861–864 (2012). https://doi.org/10.1007/s10585-012-9522-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-012-9522-0

Keywords

Search

Navigation